Our Newsletter
April 2026
Home > Newsletters > April 2026
Yesterday’s futuristic dream of gene and cell therapy is today’s reality. These transformative treatments, once limited to a few nations, are now reaching patients in India, bringing new hope to those battling rare and complex diseases.
CelAbGen is AI-Based De Novo Antibody Generation Pipeline — funded by BIRAC-DBT. It designs novel targeting antibodies and nanobodies from scratch, enabling ViroVbots to lock onto specific immune cell surface markers (CD3, CD4, CD5, CD7, CD8) with extraordinary precision. This ensures the therapy reaches T cells — and only T cells.
Our antibodies are engineered for high specificity, solubility, and develop ability — making them ideal for a wide range of applications in cell and gene therapy, including:
CelAbGen empowers researchers, biotech innovators, and clinical developers to advance antibody-based therapies with unprecedented speed, precision, and reliability.
Team Cellogen is developing an AI-powered chatbot that simplifies the complexities of cell and gene therapy. Designed in patient-friendly language, it explains how these advanced, targeted treatments work and their real-world applications. The goal is to empower patients with clear, accessible information, helping them better understand their treatment options and make informed healthcare decisions.
ViroVbots are Cellogen’s patented, AI-engineered lentiviral delivery vehicles that transform a patient’s own immune system into a living cancer-fighting army — without removing a single cell from the body. Traditional CAR-T therapy extracts a patient’s T cells, engineers them in a laboratory over 4–6 weeks, and reinfuses them — a process costing crores and accessible only in a handful of centres worldwide. ViroVbots bypass this entirely. When administered intravenously, these intelligently designed nano-agents seek out T cells directly in the bloodstream, deliver the CAR gene payload with laser precision, and generate fully functional CAR-T cells in vivo — inside the patient, in real time.
INDIA
Cellogen Introduces ViroVBots to Address India’s Growing Disease Burden Cellogen has unveiled its innovative ViroVBots platform, aimed at tackling some of India’s most pressing healthcare challenges across oncology, autoimmune, and metabolic diseases. The company positions these advanced therapies as affordable, scalable, and designed for widespread patient access. In oncology, ViroVBots target over 1.4 million new cancer cases reported annually in India. These therapies are being developed to address blood cancers, solid tumors, and multiple myeloma by targeting CAR constructs such as CD19, CD20, CD22, BCMA, CLDN, GPC3, and others—offering potential curative options where limited treatments exist today.
For autoimmune disorders, affecting more than 50 million Indians, ViroVBots focus on conditions like lupus, rheumatoid arthritis, and inflammatory bowel disease. By reprogramming or eliminating rogue immune cells with precision, the platform aims to achieve durable remission rather than long-term symptom management. In the metabolic segment, with over 101 million diabetics in India, ViroVBots are being developed to target insulin resistance and immune-metabolic dysregulation at the genetic level. The approach leverages hematopoietic stem cells and liver-cell targeting modules to enable deeper metabolic reprogramming. With this multi-disease focus, Cellogen’s ViroVBots platform signals a step toward next-generation, targeted therapies that aim to transform treatment outcomes at scale.
UNITED STATES
FDA Approves Rocket Pharmaceuticals’ Kresladi for Severe LAD-I The FDA granted accelerated approval to Kresladi (marnetegragene autotemcel), Rocket Pharmaceuticals’ lentiviral gene therapy for pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I). This rare, often fatal immune disorder previously relied on bone marrow transplants. Approval is based on increased CD18/CD11a expression; confirmatory studies are required for full approval. It marks the first gene therapy for this condition.
To Stay Updated with the latest in Cell & Gene Therapy, Subscribe to Our Newsletter
Subscribe Now >Latest Newsletters
